Alaunos Therapeutics (TCRT) Retained Earnings (2009 - 2026)

Alaunos Therapeutics has reported Retained Earnings for 18 years, with the latest figure at -$925.6 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings changed 0.45% year-over-year to -$925.6 million; the trailing twelve-month figure through Mar 2026 stood at -$925.6 million (changed 0.45% YoY), and the FY2025 full-year result was -$924.6 million, changed 0.45% from the prior year.
• Retained Earnings for Q1 2026 stood at -$925.6 million, roughly flat from -$924.6 million in the prior quarter.
• The five-year high for Retained Earnings was -$852.6 million in Q1 2022, with the low at -$925.6 million in Q1 2026.
• Historically, Retained Earnings has averaged -$904.5 million across 5 years, with a median of -$918.6 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings decreased 8.52% — and 2025, when it dropped 0.28%.
• Alaunos Therapeutics' Retained Earnings stood at -$880.6 million in 2022, then decreased by 3.99% to -$915.8 million in 2023, then decreased by 0.51% to -$920.4 million in 2024, then dropped by 0.45% to -$924.6 million in 2025, then declined by 0.11% to -$925.6 million in 2026.
• The last three Retained Earnings figures came in at -$925.6 million (Q1 2026), -$924.6 million (Q4 2025), and -$923.7 million (Q3 2025), per Business Quant data.